Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs Semaglutide in obesity/overweight
NCT05822830Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2023
- Primary completion
- Nov 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide in obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percent Change From Baseline in Body Weight at 72 weeks. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05822830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822830.